Skip to content

Serotonin: all studies

Page 255 of 401: studies 2,541 to 2,550 of 4,004, newest first. Back to the serotonin overview

Research

A choroid plexus apocrine secretion mechanism shapes CSF proteome and embryonic brain development.

bioRxiv : the preprint server for biology January 16, 2024 Ya'El Courtney, Joshua P Head, Elizabeth D Yimer et al. 9 citations preprint

We discovered that apocrine secretion by embryonic choroid plexus (ChP) epithelial cells contributes to the cerebrospinal fluid (CSF) proteome and influences brain development in mice. The apocrine response relies on sustained intracellular calcium signaling and calpain-mediated cytoskeletal remodeling. It rapidly alters the embryonic CSF proteome, activating neural progenitors lining the...

DOI: 10.1101/2024.01.08.574486 (opens in new tab) Full text (opens in new tab) Maternal health Fetal development Brain physiology Developmental biology

Synthetic surprise as the foundation of the psychedelic experience

Neuroscience & Biobehavioral Reviews January 15, 2024 Dietmar Schmitz, Roberto De Filippo 13 citations

Psychedelic agents, such as LSD and psilocybin, induce marked alterations in consciousness via activation of the 5-HT2A receptor (5-HT2ARs). We hypothesize that psychedelics enforce a state of synthetic surprise through the biased activation of the 5-HTRs system. This idea is informed by recent insights into the role of 5-HT in signaling surprise. The effects on consciousness, explained by the...

DOI: 10.1016/j.neubiorev.2024.105538 (opens in new tab) Psilocybin Predictive coding Surprise Perception +4

Enhanced visual contrast suppression during peak psilocybin effects: A psychophysical study

January 11, 2024 Link Swanson, Sophia Jungers, Ranji Varghese et al. 1 citation preprint

In visual perception, an effect known as surround suppression occurs wherein the apparent contrast of a center stimulus is reduced when it is presented within a higher-contrast surrounding stimulus. Many key aspects of visual perception involve surround suppression, yet the neuromodulatory processes involved remain unclear. Psilocybin is a serotonergic psychedelic compound known for its robust...

DOI: 10.31234/osf.io/5rm62 (opens in new tab) Psilocybin Visual hallucination Stimulus psychology Hallucinogen +7

Psilocybin Promotes Cell-Type-Specific Changes in the Orbitofrontal Cortex Revealed by Single-Nucleus RNA-seq

bioRxiv (Cold Spring Harbor Laboratory) January 7, 2024 Ziran Huang, Xiaoyan Wei, Xiaobin Wang et al. 3 citations preprint

Abstract Recent clinical breakthroughs hold great promise for the application of psilocybin in the treatments of psychological disorders, such as depression, addiction, and obsessive-compulsive disorder. Psilocybin is a psychedelic whose metabolite, psilocin, is a 5-HT 2A receptor agonist. Nevertheless, the underlying mechanisms for the effects of psilocybin on the brain are not fully...

The Psychedelic Future of Post-Traumatic Stress Disorder Treatment

Current Neuropharmacology January 5, 2024 Tamar Glatman Zaretsky, Kathleen M. Jagodnik, Robert Barsic et al. 73 citations

Abstract: Post-traumatic stress disorder (PTSD) is a mental health condition that can occur following exposure to a traumatic experience. An estimated 12 million U.S. adults are presently affected by this disorder. Current treatments include psychological therapies (e.g., exposure-based interventions) and pharmacological treatments (e.g., selective serotonin reuptake inhibitors (SSRIs))....

Exploring Predictors of Ketamine Response in Adolescent Treatment-Resistant Depression

Journal of Child and Adolescent Psychopharmacology January 3, 2024 Alice Lineham, Victor J. Avila‐quintero, Michael H. Bloch et al. 15 citations

Objective:Ketamine has proved effective as a rapid-acting antidepressant agent, but treatment is not effective for everyone (approximately a quarter to a half of patients). Some adult studies have begun to investigate predictors of ketamine's antidepressant response, but no studies have examined this in adolescents with depression. Methods:We conducted a secondary data analysis of adolescents...

Visual mismatch negativity in Parkinson's psychosis and potential for testing treatment mechanisms

Brain Communications 2024 Miriam Vignando, Dominic H Ffytche, Ndaba Mazibuko et al. 7 citations

Abstract Psychosis and visual hallucinations are a prevalent non-motor symptom of Parkinson's disease, negatively affecting patients’ quality of life and constituting a greater risk for dementia. Understanding neural mechanisms associated to these symptoms is instrumental for treatment development. The mismatch negativity is an event-related potential evoked by a violation in a sequence of...

Dextromethorphan/Bupropion: A Novel Treatment for Patients With Major Depressive Disorder

American Journal of Therapeutics 2024 Kristine C. Willett, LeDea R. Bond, Amanda M. Morrill et al.

Background: Major depressive disorder (MDD) affects millions of people and is the leading cause of disability worldwide. Patients report decreased quality of life and ability to perform activities of daily living. It is estimated that the current standard of care, which includes pharmacologic therapy with a selective serotonin reuptake inhibitor, is effective in 40%–60%. Additional treatment...

Potential therapeutic use of ayahuasca: A literature review

Acta Amazonica 2024 Salvana Priscylla Manso Costa, Keith Cardoso Carvalho, Isabella Nunes Gomes et al. 4 citations

ABSTRACT Ayahuasca is a psychoactive decoction originally used in indigenous Amazonian culture. It consists of a dense brown liquid that most frequently results from the decoction of two plants native to the Amazon rainforest, Psychotria viridis (Rubiaceae) and Banisteriopsis caapi (Malpighiaceae). The composition of the decoction is variable, as several plant species can be used in its...

Antidepressants enter cells, organelles, and membranes.

Neuropsychopharmacology 2024 Zack Blumenfeld, Kallol Bera, Eero Castrén et al. 10 citations

We begin by summarizing several examples of antidepressants whose therapeutic actions begin when they encounter their targets in the cytoplasm or in the lumen of an organelle. These actions contrast with the prevailing view that most neuropharmacological actions begin when drugs engage their therapeutic targets at extracellular binding sites of plasma membrane targets-ion channels, receptors,...